Full Press Release Details
VIENNA, Va,--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI presents Phase 3 Multikine data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival.
CVM Positive Sentiment
CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
Key Takeaway: CEL-SCI presented new Phase 3 data for Multikine at the World Congress. The study highlighted that pre-surgical biomarkers can identify head and neck cancer patients who achieve a 73% five-year survival rate. This data may enhance patient selection for treatment.
Market Sentiment Analysis
POSITIVE FACTORS
- CEL-SCI presented promising Phase 3 Multikine data.
- 73% 5-year survival rate for head and neck cancer patients.
- Pre-surgical biomarkers effectively identify patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~3 mo
High dilution risk
Lead asset
LI
Phase 3 · Squamous Cell Carcinoma of the Oral Cavity
Frequently Asked Questions
What was presented at the World Congress?
CEL-SCI presented Phase 3 Multikine data.
What survival rate was achieved in the study?
The study reported a 73% five-year survival rate.
What type of cancer was focused on?
The focus was on head and neck cancer patients.
How do pre-surgical biomarkers help?
They identify patients likely to achieve better survival rates.